- Home
- Publications
- Publication Search
- Publication Details
Title
A Perspective of Immunotherapy for Prostate Cancer
Authors
Keywords
-
Journal
Cancers
Volume 8, Issue 7, Pages 64
Publisher
MDPI AG
Online
2016-07-07
DOI
10.3390/cancers8070064
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).
- (2017) Susan F. Slovin et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in immunotherapy for melanoma
- (2016) Jason M. Redman et al. BMC Medicine
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chimeric antigen receptor-modified T cells strike back
- (2016) Matthew J. Frigault et al. INTERNATIONAL IMMUNOLOGY
- The immune system and cancer evasion strategies: therapeutic concepts
- (2016) S. Muenst et al. JOURNAL OF INTERNAL MEDICINE
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
- (2015) Consuelo Buttigliero et al. CANCER TREATMENT REVIEWS
- The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
- (2015) H. Gevensleben et al. CLINICAL CANCER RESEARCH
- A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
- (2015) E. J. Small et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma
- (2015) R. J. Sullivan et al. CLINICAL CANCER RESEARCH
- Combining Immunotherapy and Radiation for Prostate Cancer
- (2015) Steven E. Finkelstein et al. Clinical Genitourinary Cancer
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Adoptive T-cell therapy for cancer: The era of engineered T cells
- (2015) Chiara Bonini et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Emerging therapeutic approaches in renal cell carcinoma
- (2015) Hiral Parekh et al. Expert Review of Anticancer Therapy
- Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions
- (2015) Xiao X Wei et al. Expert Review of Vaccines
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer
- (2015) Rebecca L. Prue et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Vaccines, Adjuvants, and Dendritic Cell Activators—Current Status and Future Challenges
- (2015) Joseph Obeid et al. SEMINARS IN ONCOLOGY
- Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
- (2015) Edward B. Garon SEMINARS IN ONCOLOGY
- Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies
- (2015) Sergio Bracarda et al. SEMINARS IN ONCOLOGY
- Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
- (2015) Francesco Massari et al. Targeted Oncology
- Engineering CAR-T cells: Design concepts
- (2015) Shivani Srivastava et al. TRENDS IN IMMUNOLOGY
- Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer
- (2015) Fred Saad et al. UROLOGY
- Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
- (2015) Michal Podrazil et al. Oncotarget
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
- (2014) C. Lebbe et al. ANNALS OF ONCOLOGY
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer
- (2014) Manja Idorn et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunotherapy in prostate cancer: review of the current evidence
- (2014) E. M. Fernández-García et al. Clinical & Translational Oncology
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Therapeutic vaccines for cancer: an overview of clinical trials
- (2014) Ignacio Melero et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Current Perspectives on Immunotherapy
- (2014) Jeffrey S. Weber SEMINARS IN ONCOLOGY
- Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work.
- (2014) Andrew J. Armstrong et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The Role of M1 and M2 Macrophages in Prostate Cancer in relation to Extracapsular Tumor Extension and Biochemical Recurrence after Radical Prostatectomy
- (2014) M. Lanciotti et al. Biomed Research International
- From Bench to Bedside: Immunotherapy for Prostate Cancer
- (2014) Brian Wan-Chi Tse et al. Biomed Research International
- Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
- (2014) L. Shen et al. Cancer Immunology Research
- Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
- (2014) Stefanie J Mandl et al. Journal for ImmunoTherapy of Cancer
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Antibody-based immunotherapy for ovarian cancer: where are we at?
- (2013) B. W. C. Tse et al. ANNALS OF ONCOLOGY
- Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2013) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
- (2013) Omid Hamid et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Exploiting the curative potential of adoptive T-cell therapy for cancer
- (2013) Christian S. Hinrichs et al. IMMUNOLOGICAL REVIEWS
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature
- (2013) Shujing Shi et al. MEDICAL ONCOLOGY
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complete Biochemical (Prostate-specific Antigen) Response to Sipuleucel-T With Enzalutamide in Castration-resistant Prostate Cancer: A Case Report With Implications for Future Research
- (2013) Julie N. Graff et al. UROLOGY
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
- (2013) J. L. Gulley et al. Cancer Immunology Research
- PD-1 as a potential target in cancer therapy
- (2013) David F. McDermott et al. Cancer Medicine
- Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
- (2012) X. Yao et al. BLOOD
- Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
- (2012) J. T. Isaacs et al. CANCER RESEARCH
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Development of Novel Immune Interventions for Prostate Cancer
- (2012) Neeraj Agarwal et al. Clinical Genitourinary Cancer
- High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
- (2012) Anna Flammiger et al. EUROPEAN JOURNAL OF CANCER
- Poxviral vectors for cancer immunotherapy
- (2012) Joseph W Kim et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
- (2012) Richard A. Morgan et al. HUMAN GENE THERAPY
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development
- (2012) R. J. Kelly et al. MOLECULAR CANCER THERAPEUTICS
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
- (2012) Suzanne Ostrand-Rosenberg et al. SEMINARS IN CANCER BIOLOGY
- An overview of sipuleucel-T: Autologous cellular immunotherapy for prostate cancer
- (2012) Johnna Wesley et al. Human Vaccines & Immunotherapeutics
- In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer
- (2012) Anna R. Kwilas Frontiers in Oncology
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
- (2011) R. J. Brentjens et al. BLOOD
- Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
- (2011) Douglas G. McNeel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Current Vaccination Strategies for Prostate Cancer
- (2011) Steven Joniau et al. EUROPEAN UROLOGY
- Prostate cancer and inflammation: the evidence
- (2011) Karen S Sfanos et al. HISTOPATHOLOGY
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- (2011) Roberto Pili et al. JOURNAL OF CLINICAL ONCOLOGY
- S100A8 and S100A9: New Insights into Their Roles in Malignancy
- (2011) Geetha Srikrishna Journal of Innate Immunity
- Cancer immunology—analysis of host and tumor factors for personalized medicine
- (2011) Shuji Ogino et al. Nature Reviews Clinical Oncology
- Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know
- (2011) Steven A. Rosenberg Nature Reviews Clinical Oncology
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts
- (2011) Susan L. Dalrymple et al. PROSTATE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer
- (2011) Robert B. Sims VACCINE
- Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer
- (2010) Norio Nonomura et al. BJU INTERNATIONAL
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
- (2010) Axel Heidenreich et al. EUROPEAN UROLOGY
- The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer
- (2010) John T Isaacs EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Prognostic significance of regulatory T cells in tumor
- (2010) Cailin Moira Wilke et al. INTERNATIONAL JOURNAL OF CANCER
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
- (2010) John A. Craddock et al. JOURNAL OF IMMUNOTHERAPY
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
- (2010) V Hoyos et al. LEUKEMIA
- Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
- (2010) Anders Olsson et al. Molecular Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
- (2009) A. Di Stasi et al. BLOOD
- Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
- (2009) O Bratt et al. BRITISH JOURNAL OF CANCER
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
- (2009) James L. Gulley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
- (2009) L. Fong et al. CANCER RESEARCH
- The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
- (2009) Lina Matera CANCER TREATMENT REVIEWS
- Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells
- (2009) A. P. Rapoport et al. CLINICAL CANCER RESEARCH
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
- (2009) Ravi A Madan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- Immunotherapy for Prostate Cancer: Walk, Don't Run
- (2009) Charles G. Drake JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
- (2009) Xiao-Song Zhong et al. MOLECULAR THERAPY
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
- (2009) Per Björk et al. PLOS BIOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
- (2008) Celestia S. Higano et al. CANCER
- Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma
- (2008) Mahmoud-Rezk A. Hussein et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
- (2008) Pingyan Cheng et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search